WITHDRAWN: FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma
UPDATE: On May 16, 2024, the FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or …